Patent · US Active

CYFRA 21-1 as a marker for colorectal cancer

US7731938B2 · kind B2 · utility

2Cited by

0References

3Claims

0Family size

Assignee

Roche Diagnostics Operations, Inc. · US

Inventors

Johann Karl · Peißenberg, DE
Herbert Andres · Penzberg, DE
Veit Peter Grunert · Munich, DE
Wolfgang Rollinger · Polling, DE
Werner Zolg · Weilheim in Oberbayern, DE

Key dates

Filing date	Jun 19, 2007
Grant date	Jun 8, 2010
Priority date	—
Expiry date	Aug 25, 2027

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/4742
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present invention relates to the assessment of colorectal cancer. It discloses the use of the CYFRA 21-1 assay in the assessment of colorectal cancer. It also relates to a method for assessing colorectal cancer in vitro using a liquid sample, derived from an individual by measuring CYFRA 21-1 in said sample. Measurement of CYFRA 21-1 can, e.g., be used in the early detection or in the follow-up of patients with colorectal cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.